Why use Retrogenix?
Our unique Cell Microarray technology identifies primary receptors and any potential secondary targets with a high degree of specificity and sensitivity, providing valuable data that can inform lead selection, assist with safety assessment and support regulatory submissions.
Retrogenix’s specificity data have been readily accepted in applications for clinical trials and marketing approval in the US (FDA), Europe (EMA), China (NMPA) & Japan (PMDA). Further details can be found in our case study using the link below. Or, to ask a question, please get in touch with a member of our team.